001     1019089
005     20240116084327.0
024 7 _ |a 10.1002/hbm.26206
|2 doi
024 7 _ |a 1065-9471
|2 ISSN
024 7 _ |a 1097-0193
|2 ISSN
024 7 _ |a 10.34734/FZJ-2023-05142
|2 datacite_doi
024 7 _ |a 36649260
|2 pmid
024 7 _ |a WOS:000987490900001
|2 WOS
037 _ _ |a FZJ-2023-05142
082 _ _ |a 610
100 1 _ |a Premi, Enrico
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Unravelling neurotransmitters impairment in primary progressive aphasias
260 _ _ |a New York, NY
|c 2023
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1702546058_9248
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Primary progressive aphasias (PPAs) are a group of neurodegenerative diseases mainly characterized by language impairment, and with variably presence of dysexecutive syndrome, behavioural disturbances and parkinsonism. Detailed knowledge of neurotransmitters impairment and its association with clinical features hold the potential to develop new tailored therapeutic approaches. In the present study, we applied JuSpace toolbox, which allowed for cross-modal correlation of magnetic resonance imaging (MRI)-based measures with nuclear imaging derived estimates covering various neurotransmitter systems including dopaminergic, serotonergic, noradrenergic, GABAergic and glutamatergic neurotransmission. We included 103 PPA patients and 80 age-matched healthy controls (HC). We tested if the spatial patterns of grey matter volume (GMV) alterations in PPA patients (relative to HC) are correlated with specific neurotransmitter systems. As compared to HC, voxel-based brain changes in PPA were significantly associated with spatial distribution of serotonin, dopamine, and glutamatergic pathways (p < .05, False Discovery Rate corrected-corrected). Disease severity was negatively correlated with the strength of GMV colocalization of D1 receptors (p = .035) and serotonin transporter (p = .020). Moreover, we observed a significant negative correlation between positive behavioural symptoms, as measured with Frontal Behavioural Inventory, and GMV colocalization of D1 receptors (p = .007) and serotonin transporter (p < .001). This pilot study suggests that JuSpace is a helpful tool to indirectly assess neurotransmitter deficits in neurodegenerative dementias and may provide novel insight into disease mechanisms and associated clinical features.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Dukart, Juergen
|0 P:(DE-Juel1)177772
|b 1
700 1 _ |a Mattioli, Irene
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Libri, Ilenia
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Pengo, Marta
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Gadola, Yasmine
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Cotelli, Maria
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Manenti, Rosa
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Binetti, Giuliano
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Gazzina, Stefano
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Alberici, Antonella
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Magoni, Mauro
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Koch, Giacomo
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Gasparotti, Roberto
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Padovani, Alessandro
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Borroni, Barbara
|0 P:(DE-HGF)0
|b 15
|e Corresponding author
773 _ _ |a 10.1002/hbm.26206
|g Vol. 44, no. 6, p. 2245 - 2253
|0 PERI:(DE-600)1492703-2
|n 6
|p 2245 - 2253
|t Human brain mapping
|v 44
|y 2023
|x 1065-9471
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.pdf
856 4 _ |y OpenAccess
|x icon
|u https://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|u https://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|u https://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.jpg?subformat=icon-640
909 C O |o oai:juser.fz-juelich.de:1019089
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)177772
910 1 _ |a Barbara Borroni, Clinica Neurologica, Università degli Studi di Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy.
|0 I:(DE-HGF)0
|b 15
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-09-27T20:46:01Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-25
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-25
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-25
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-25
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HUM BRAIN MAPP : 2022
|d 2023-08-25
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-09-27T20:46:01Z
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2022-09-27T20:46:01Z
920 _ _ |l no
920 1 _ |0 I:(DE-Juel1)INM-7-20090406
|k INM-7
|l Gehirn & Verhalten
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-7-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21